PL4364801T3 - Zoptymalizowane dawkowanie diaminofenotiazyn w populacjach - Google Patents
Zoptymalizowane dawkowanie diaminofenotiazyn w populacjachInfo
- Publication number
- PL4364801T3 PL4364801T3 PL24161558.2T PL24161558T PL4364801T3 PL 4364801 T3 PL4364801 T3 PL 4364801T3 PL 24161558 T PL24161558 T PL 24161558T PL 4364801 T3 PL4364801 T3 PL 4364801T3
- Authority
- PL
- Poland
- Prior art keywords
- diaminophenothiazines
- populations
- optimised
- dosage
- optimised dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/29—Mineral substances, e.g. mineral oils or clays
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1812193.9A GB201812193D0 (en) | 2018-07-26 | 2018-07-26 | Optimised dosage of diaminophenothiazines in populations |
| GBGB1909458.0A GB201909458D0 (en) | 2019-07-01 | 2019-07-01 | Optimised dosage of diaminophenothiazines in populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4364801T3 true PL4364801T3 (pl) | 2026-04-27 |
Family
ID=67587720
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL24161558.2T PL4364801T3 (pl) | 2018-07-26 | 2019-07-18 | Zoptymalizowane dawkowanie diaminofenotiazyn w populacjach |
| PL19752425.9T PL3826639T3 (pl) | 2018-07-26 | 2019-07-18 | Zoptymalizowane dawkowanie diaminofenotiazyn w populacjach |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19752425.9T PL3826639T3 (pl) | 2018-07-26 | 2019-07-18 | Zoptymalizowane dawkowanie diaminofenotiazyn w populacjach |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12280061B2 (pl) |
| EP (3) | EP4364801B1 (pl) |
| JP (2) | JP7465861B2 (pl) |
| KR (1) | KR20210038586A (pl) |
| CN (1) | CN112805008A (pl) |
| AU (2) | AU2019308873B2 (pl) |
| BR (1) | BR112021000802A2 (pl) |
| CA (1) | CA3106152A1 (pl) |
| DK (3) | DK4364801T3 (pl) |
| ES (3) | ES2989458T3 (pl) |
| FI (3) | FI4385512T3 (pl) |
| HR (3) | HRP20241360T1 (pl) |
| IL (1) | IL280361B2 (pl) |
| MX (2) | MX2021000894A (pl) |
| PL (2) | PL4364801T3 (pl) |
| PT (3) | PT4364801T (pl) |
| SG (1) | SG11202100333XA (pl) |
| SI (3) | SI4364801T1 (pl) |
| WO (1) | WO2020020751A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
| GB201909493D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB202006659D0 (en) | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| MX2022013884A (es) * | 2020-05-05 | 2022-11-30 | Wista Lab Ltd | Compuestos de metiltioninio para usarse en el tratamiento de hipoxemia. |
| KR20230012514A (ko) * | 2020-05-05 | 2023-01-26 | 위스타 레보레이토리스 리미티드 | 치료방법 |
| AU2023279800A1 (en) | 2022-05-31 | 2024-12-19 | TauRx Therapeutics Management Ltd | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| EP4590306A1 (en) | 2022-09-21 | 2025-07-30 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| PT1509232E (pt) | 2002-05-31 | 2009-01-07 | Lundbeck & Co As H | Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer |
| SI2322517T1 (sl) | 2004-09-23 | 2019-06-28 | Wista Laboratories Ltd. | Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC) |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| SI2004155T1 (en) | 2006-03-29 | 2018-05-31 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
| WO2007110630A1 (en) | 2006-03-29 | 2007-10-04 | Wista Laboratories Ltd. | Thioninium compounds and their use |
| MY148145A (en) | 2006-07-11 | 2013-03-15 | Wista Lab Ltd | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| WO2010078659A1 (en) | 2009-01-12 | 2010-07-15 | Foster Health Inc. | Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions |
| WO2010104375A1 (en) * | 2009-03-12 | 2010-09-16 | N.V. Nutricia | Stigmasterol for the treatment of alzheimer's disease |
| JP5918136B2 (ja) | 2009-09-24 | 2016-05-18 | ウィスタ ラボラトリーズ リミテッド | プロセス |
| DE102010062810B4 (de) | 2010-09-07 | 2014-03-13 | Immungenetics Ag | 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| US10472340B2 (en) | 2015-02-17 | 2019-11-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Substituted phenothiazines as mitochondrial agents |
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
-
2019
- 2019-07-18 FI FIEP24161602.8T patent/FI4385512T3/fi active
- 2019-07-18 US US17/262,902 patent/US12280061B2/en active Active
- 2019-07-18 SI SI201931008T patent/SI4364801T1/sl unknown
- 2019-07-18 FI FIEP19752425.9T patent/FI3826639T3/fi active
- 2019-07-18 HR HRP20241360TT patent/HRP20241360T1/hr unknown
- 2019-07-18 EP EP24161558.2A patent/EP4364801B1/en active Active
- 2019-07-18 CA CA3106152A patent/CA3106152A1/en active Pending
- 2019-07-18 MX MX2021000894A patent/MX2021000894A/es unknown
- 2019-07-18 HR HRP20251694TT patent/HRP20251694T1/hr unknown
- 2019-07-18 DK DK24161558.2T patent/DK4364801T3/da active
- 2019-07-18 DK DK19752425.9T patent/DK3826639T3/da active
- 2019-07-18 FI FIEP24161558.2T patent/FI4364801T3/fi active
- 2019-07-18 JP JP2021502770A patent/JP7465861B2/ja active Active
- 2019-07-18 ES ES19752425T patent/ES2989458T3/es active Active
- 2019-07-18 SI SI201931013T patent/SI4385512T1/sl unknown
- 2019-07-18 HR HRP20260059TT patent/HRP20260059T1/hr unknown
- 2019-07-18 IL IL280361A patent/IL280361B2/en unknown
- 2019-07-18 PL PL24161558.2T patent/PL4364801T3/pl unknown
- 2019-07-18 PT PT241615582T patent/PT4364801T/pt unknown
- 2019-07-18 ES ES24161602T patent/ES3060455T3/es active Active
- 2019-07-18 EP EP19752425.9A patent/EP3826639B1/en active Active
- 2019-07-18 KR KR1020217005178A patent/KR20210038586A/ko not_active Ceased
- 2019-07-18 DK DK24161602.8T patent/DK4385512T3/da active
- 2019-07-18 WO PCT/EP2019/069428 patent/WO2020020751A1/en not_active Ceased
- 2019-07-18 ES ES24161558T patent/ES3060453T3/es active Active
- 2019-07-18 BR BR112021000802-0A patent/BR112021000802A2/pt unknown
- 2019-07-18 CN CN201980061773.1A patent/CN112805008A/zh active Pending
- 2019-07-18 PT PT197524259T patent/PT3826639T/pt unknown
- 2019-07-18 PT PT241616028T patent/PT4385512T/pt unknown
- 2019-07-18 SI SI201930844T patent/SI3826639T1/sl unknown
- 2019-07-18 SG SG11202100333XA patent/SG11202100333XA/en unknown
- 2019-07-18 EP EP24161602.8A patent/EP4385512B1/en active Active
- 2019-07-18 PL PL19752425.9T patent/PL3826639T3/pl unknown
- 2019-07-18 AU AU2019308873A patent/AU2019308873B2/en active Active
-
2021
- 2021-01-22 MX MX2023009856A patent/MX2023009856A/es unknown
-
2022
- 2022-10-07 US US17/961,961 patent/US12263175B2/en active Active
-
2024
- 2024-04-01 JP JP2024058998A patent/JP7763890B2/ja active Active
-
2025
- 2025-02-26 US US19/063,699 patent/US20250302843A1/en active Pending
- 2025-06-17 AU AU2025204524A patent/AU2025204524A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280361A (en) | Optimal dosage of diaminophenothiazines in populations | |
| HRP20210144T8 (hr) | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka | |
| PT3368017T (pt) | Comprimido otimizado de dosagem elevada que contém messalazina | |
| GB2539986B (en) | Enhanced rates of pregnancy and rates of embryo implantation | |
| EP3866770C0 (en) | NEW DOSAGE FORM | |
| GB201812193D0 (en) | Optimised dosage of diaminophenothiazines in populations | |
| GB201909458D0 (en) | Optimised dosage of diaminophenothiazines in populations | |
| PL3341481T3 (pl) | Kompozycja antysensowna mikrorna-328 i zastosowanie terapeutyczne | |
| PT3866775T (pt) | Cisteamina para utilização no tratamento de doenças pulmonares | |
| GB201808507D0 (en) | Dosage Regime | |
| GB201808473D0 (en) | Dosage regime | |
| GB201808101D0 (en) | Dosage regime | |
| GB201803298D0 (en) | Dosage regime | |
| GB201802679D0 (en) | Dosage regime | |
| AU201814965S (en) | Alu chair | |
| GB201720542D0 (en) | Dosage regime | |
| GB201720544D0 (en) | Dosage regime | |
| GB201720543D0 (en) | Dosage regime | |
| GB201720541D0 (en) | Dosage regime | |
| AU364005S (en) | Alu' sling armchair | |
| GB201710494D0 (en) | Dosage regime | |
| GB201710496D0 (en) | Dosage regime | |
| GB201710495D0 (en) | Dosage regime | |
| GB201709441D0 (en) | Dosage regime | |
| GB201709439D0 (en) | Dosage regime |